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Reply
We appreciate Dr Verdant’s comments regarding our recent
article describing our experience with endovascular stent graft
repair of thoracic aortic aneurysms. There are a few comments we
would specifically like to address.
Dr Verdant states that we have clearly established the “poor
performance” of this technology, implying that the 33% mortality
at 40 months is aneurysm related. This is incorrect. As is clearly
stated in the article, 6 deaths were attributable to aneurysm-related
causes. The rest were from underlying comorbid medical illnesses.
With regards to the Type I endoleak rate, we have adopted a more
liberal approach to performing combined open and endovascular
repairs of thoracic aneurysms. Since the time of publication, we
have enrolled 18 more patients in our protocol, all using the Talent
device. Of these 18 patients, 7 had their stent graft as the second
stage of an elephant trunk repair. The results in these 18 patients
have been heartening. We achieved primary clinical success in 17;
in 1 patient, we were unable to deliver the device due to aortic
tortuosity. There were 2 mortalities in this cohort: 1 from infective
endocarditis which was present at the time of initial presentation,
and 1 from a ruptured infrarenal aneurysm. There were no major
procedure-related morbidities. There were no thoracic aneurysm–
or device-related deaths. There were no Type I or Type III
endoleaks.
We agree wholeheartedly with Dr Verdant’s sentiment that
these cases should be done in “highly specialized centers for aortic
surgery equipped with fully trained personnel and optimal meth-
ods of organ protection.” As a matter of fact, our multidisciplinary
team includes a group of cardiac surgeons with extensive experi-
ence in open thoracic aneurysm repair. The cases are reviewed as a
group, and the most appropriate course of therapy is decided upon.
Thoracic stent-graft technology is still very much in evolution,
and we recognize that it is still investigational. One of the goals of
our article was to bring to light the limitations of current technol-
ogy. However, one should be careful not to “throw out the baby
with the bathwater.” Dr Verdant states that any “technique of graft
insertion in which the adventitia is . . . excluded is doomed to
failure.” Clinical data clearly suggests otherwise. The evolving
experience with endovascular stent-graft repair of infrarenal ab-
dominal aortic aneurysms has shown us that endoluminal aneu-
rysm exclusion results in a durable and safe repair with decreased
morbidity in properly selected patients.1 We feel confident that
with improvements in patient selection, device delivery systems,
and stent-graft design, the same will be true for the thoracic aorta.
The analogy can be made to the evolution of the prosthetic
cardiac valve, a process that took more than 15 years. Think how
many people would not be alive today if the development process
had been abandoned because of early failures.
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Regarding “Randomized trial and local biological
effect of autologous platelets used as adjuvant therapy
for chronic venous leg ulcers”
We read with the greatest interest the paper recently published
by Senet et al (J Vasc Surg 2003;38:1342-8). We appreciated the
very professional way used to assess the in vivo and in vitro capacity
(or incapacity) for platelet concentrate to enhance healing of
chronic ulcers. However, their results are quite different from our
own.
We have used platelet gel in clinical practice since 2000.
Platelet gel is a semisolid product obtained by activating autolo-
gous platelet concentrates with an autologous thrombin precursor
obtained by recalcification of autologous plasma. We obtain autol-
ogous platelets by processing either tubes or blood bag–collected
blood according to the necessary platelet gel volume or patient
conditions. Fresh or cryopreserved platelets are interchangeably
used, platelet-derived growth factors being quite thermostable.1,2
Whichever the blood collection system—tube differential centrif-
ugation or buffy-coat derived platelets as described by Senet et
al—we resuspend platelets in autologous plasma at the final con-
centration of 1-2 10/mL. So two main differences exist between
Senet et al’s platelet preparation and ours: we resuspend platelets in
fresh autologous plasma instead of saline, and the final platelet
concentration in our product actually is two to four times more
concentrated.
Senet et al treated lesions with 107 platelets/cm2. We treat
lesions with platelet gel containing 0.3-0.4  10 platelets/cm,
which is approximately 40 times the platelet amount used by Senet
and colleagues. Finally, we dress ulcerative lesions once per week
instead of 3 times per week.
In vitro experiments have shown that proliferation of human
fibroblast is strongly enhanced by addition of crude platelet lysate
to the culture medium. Proliferation rate is dose and time depen-
dent. The proliferation level is maximal between culture day 7 and
11. In our in-vitro experiments the proliferation rate was clearly
dose dependent, from 5% to 30% (platelet lysate/culture medium,
v/v considering 0% no addition of platelet lysate) (Fig). All of this
taken together may explain why Senet and colleagues obtained
negligible results in vivo and in vitro, in spite their highly profes-
sional experimental trial, while in our hands more than 85% of
patients respond to treatment and the healing time is roughly
halved.
We are confident that Senet and colleagues did not obtain
noticeable results either in vivo or in vitro simply because they used
platelet concentrates under the limit of biological activity of
JOURNAL OF VASCULAR SURGERY
May 20041146 Letters to the Editor
